As required by SEA 246, passed in the 2013 General Assembly, the Medical Licensing Board (MLB) of Indiana is meeting this summer to establish standards and protocols for the prescribing of controlled substances in the state.
|Muncie's Robert Darroca, M.D., represents the ISMA during the July 24 MLB meeting.
A large number of physicians attended the MLB's July 24 meeting, including Gordon Hughes, M.D., ISMA president; Robert Darroca, M.D.; and Randy Stevens, M.D., representing the ISMA, as well as Mike Rinebold, director of Government Relations.
ISMA member Deborah McMahan, M.D., chair of the Education Subcommittee of the Indiana Prescription Drug Abuse Task Force, responded to questions regarding the proposed draft jointly submitted by the ISMA and the Office of the Indiana Attorney General (OIAG). View the draft here.
Other organizations testifying included the Indiana Health Care Association, Indiana Academy of Family Physicians, Indiana Hospice, Indiana Pharmacy Board and Indiana Hospital Association.
You can help
The MLB has asked for comments to be submitted for members to consider at the next public hearing set for Aug. 22. Send comments to President Steve Huddleston.
The ISMA House of Delegates will consider a resolution regarding the rule and a “toolkit” during the ISMA Annual Convention Sept. 20-22. The MLB will adopt the rule officially Sept. 26 to comply with the Nov.1 deadline and Dec. 15 enforcement date set by law.
The MLB also heard testimony from the ISMA and the OIAG on a proposed rule regarding the MLB approving a petition permitting the OIAG an “examination authorization.” Learn more.
Here is new information you may see on your Controlled Substance Registration renewal.
Acknowledgements for CSR renewal
I acknowledge that controlled substances have great potential to harm patients.
I acknowledge that there are effective modalities available to manage chronic pain and maximize patient functionality.
I acknowledge that the Indiana Scheduled Prescription Electronic Collection and Tracking program (INSPECT) collects and monitors controlled substances prescription data and has been proven to be an effective tool when prescribing controlled substances.
I acknowledge that both ACOG and the AMA clearly state there is an ethical duty to screen every obstetrical patient for substance use, including at the first prenatal or intake visit, and at least once per trimester thereafter.